HK1214921A1 - 用於利用羧胺三唑乳清酸鹽治療對先前化學治療藥物和靶向藥物具有獲得性耐藥性的癌症的方法和組合物 - Google Patents

用於利用羧胺三唑乳清酸鹽治療對先前化學治療藥物和靶向藥物具有獲得性耐藥性的癌症的方法和組合物

Info

Publication number
HK1214921A1
HK1214921A1 HK16102855.2A HK16102855A HK1214921A1 HK 1214921 A1 HK1214921 A1 HK 1214921A1 HK 16102855 A HK16102855 A HK 16102855A HK 1214921 A1 HK1214921 A1 HK 1214921A1
Authority
HK
Hong Kong
Prior art keywords
chemotherapeutic
compositions
methods
acquired resistance
treating cancers
Prior art date
Application number
HK16102855.2A
Other languages
English (en)
Inventor
Rashida A Karmali
Original Assignee
Tactical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tactical Therapeutics Inc filed Critical Tactical Therapeutics Inc
Publication of HK1214921A1 publication Critical patent/HK1214921A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK16102855.2A 2013-04-01 2016-03-11 用於利用羧胺三唑乳清酸鹽治療對先前化學治療藥物和靶向藥物具有獲得性耐藥性的癌症的方法和組合物 HK1214921A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/986,103 US9089570B2 (en) 2010-09-03 2013-04-01 Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
PCT/US2014/032253 WO2014165412A2 (en) 2013-04-01 2014-03-28 Methods and compositions for treating cancers having acquired resistance to chemotherapeutic and targeted drugs using carboxyamidotriazole orotate

Publications (1)

Publication Number Publication Date
HK1214921A1 true HK1214921A1 (zh) 2016-08-12

Family

ID=51621074

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16102855.2A HK1214921A1 (zh) 2013-04-01 2016-03-11 用於利用羧胺三唑乳清酸鹽治療對先前化學治療藥物和靶向藥物具有獲得性耐藥性的癌症的方法和組合物

Country Status (11)

Country Link
US (1) US9089570B2 (zh)
EP (1) EP2981169B1 (zh)
JP (1) JP6410795B2 (zh)
KR (2) KR20210019116A (zh)
CN (1) CN105120663B (zh)
AU (1) AU2014248377B2 (zh)
CA (1) CA2902144C (zh)
HK (1) HK1214921A1 (zh)
IL (1) IL241827B (zh)
WO (1) WO2014165412A2 (zh)
ZA (1) ZA201506037B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3936145A1 (en) * 2014-07-31 2022-01-12 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
US10548986B2 (en) 2016-03-02 2020-02-04 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
CN107890467A (zh) * 2017-11-24 2018-04-10 中国医学科学院基础医学研究所 干扰能量代谢的药物在胰腺癌复发中的应用
US20220168276A1 (en) * 2020-08-05 2022-06-02 Tactical Therapeotics Inc. Mehods and Compositions for Treating SARS-CoV-2 Infection using Carboxyamidotriazole Orotate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0840608B1 (en) * 1995-07-21 2004-10-06 Savvipharm Inc. Orotate salts of 5-amino or substituted amino 1,2,3-triazoles for treatment of neoplasms
US5728707A (en) 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US8034823B2 (en) * 2005-02-22 2011-10-11 Savvipharm Inc Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
US7750018B2 (en) * 2006-12-06 2010-07-06 Tactical Therapeutics, Inc Use of carboxiamidotriazole (CAI) orotate in macular degeneration
CA2695995C (en) * 2007-08-13 2015-09-29 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CN101669941B (zh) * 2008-09-09 2012-11-07 中国医学科学院基础医学研究所 一种联合用药治疗恶性肿瘤的方法以及抗恶性肿瘤的药物
US8877785B2 (en) * 2009-09-04 2014-11-04 Tactical Therapeutics Inc Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate
MX2012002730A (es) * 2009-09-04 2012-07-20 Tactical Therapeutics Inc Nuevas composiciones y procesos para preparar formulaciones de 1,2,3-triazoles 5-amino o amino sustituidos y triazol orotato.

Also Published As

Publication number Publication date
EP2981169A2 (en) 2016-02-10
CA2902144C (en) 2021-02-09
US20140294806A1 (en) 2014-10-02
JP2016515619A (ja) 2016-05-30
ZA201506037B (en) 2021-09-29
EP2981169B1 (en) 2021-05-05
JP6410795B2 (ja) 2018-10-24
US9089570B2 (en) 2015-07-28
CN105120663B (zh) 2017-08-04
WO2014165412A2 (en) 2014-10-09
CA2902144A1 (en) 2014-10-09
CN105120663A (zh) 2015-12-02
WO2014165412A3 (en) 2015-01-29
KR20160026824A (ko) 2016-03-09
IL241827B (en) 2019-02-28
AU2014248377A1 (en) 2015-09-03
EP2981169A4 (en) 2016-09-14
KR20210019116A (ko) 2021-02-19
AU2014248377B2 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
HK1222981A1 (zh) 多價和單價多特異性複合物及其用途
HK1220916A1 (zh) 治療癌症和預防癌症藥物抗性的方法
HK1214533A1 (zh) 治療癌症和預防癌症耐藥性的方法
HK1222097A1 (zh) 用於吞嚥困難患者的營養的組合物
ZA201505735B (en) Cancer drug and uses
HK1213180A1 (zh) 治療和預防癌症藥物抗性的方法
ZA201602380B (en) Cancer treatment with combination of plinabulin and taxane
HK1221424A1 (zh) 治療癌症的藥物組合
HK1211235A1 (zh) 治療癌症和預防藥物抗性的方法
HK1221145A1 (zh) 用二氫吡嗪並-吡嗪治療癌症
HK1211963A1 (zh) 用於肝癌診斷和治療的組合物和方法
HK1221150A1 (zh) 用二氫吡嗪並-吡嗪類對癌症的治療
HK1217650A1 (zh) 用於治療劇痛的組合物及方法
HRP20182145T1 (hr) Antitumorni agens koji uključuje irinotekan hidroklorid hidrat u niskoj dozi
HK1225647A1 (zh) 用於治療癌症的組合物和方法
IL242533B (en) Naltrexone cancer treatment
HK1214921A1 (zh) 用於利用羧胺三唑乳清酸鹽治療對先前化學治療藥物和靶向藥物具有獲得性耐藥性的癌症的方法和組合物
GB201303184D0 (en) Treatment of cancer
HK1214502A1 (zh) 用於癌症治療的 和卡培他濱的組合
TWI561255B (en) Use of umirolimus and its derivatives for treating cancer
GB201322958D0 (en) Uses of oligouronates in cancer treatment
GB201312336D0 (en) Detection of Brain Cancer
SG10201802995SA (en) Cancer treatment with combination of plinabulin and taxane
TWM475359U (en) Improved structure of album
GB201308529D0 (en) Treatment of cancer